Atalanta Therapeutics has bagged $97 million, money the biotech plans to use to launch clinical trials for its small ...

After 20 years of building radioisotope expertise as a manufacturer and supplier, German firm ITM Isotope Technologies is ...

Takeda is taking back the home license for a phase 3-ready depression drug as part of an amendment to its multi-asset ...

Just days after President Trump imposed broad restrictions on communications, meetings, travel and public appearances at the ...

Maze Therapeutics has set out plans for a $131 million IPO as the company prepares to start dosing its lead kidney drug in a ...

The author of the seminal cancer biography The Emperor Of All Maladies and the co-founder of LinkedIn are looking to connect ...

Cell therapy biotech Aurion is moving forward with plans to IPO despite a pending lawsuit from one of its existing investors.

Metsera has set its sights on a hefty $289 million IPO as the next-gen obesity biotech seeks to fund a phase 3 trial of its ...

The FDA has tapped Sara Brenner to serve as acting commissioner as it awaits new leadership from the Trump administration to ...

Allakos is throwing in the towel. After seeing phase 1 data in hives, the biotech has decided to drop the drug candidate and ...